Eli Lilly and Co

HAYA Therapeutics announced a multi-year agreement with Eli Lilly to apply its RNA-guided regulatory genome platform for preclinical drug discovery in obesity and metabolic conditions, potentially earning up to $1 billion in payments and royalties. Wilson Sonsini Goodrich & Rosati advised HAYA on patent matters, led by Minyoung Shin, Mike Hostetler, Esther Cynn, Tiara Wong, and Jen Zeng.

Eli Lilly's QWINT-1 and QWINT-3 trials show once-weekly insulin efsitora alfa (efsitora) is non-inferior to daily basal insulins for type 2 diabetes, with potential to simplify insulin therapy and reduce patient burden.

Eli Lilly's weekly insulin efsitora shows similar efficacy to daily insulin in type 2 diabetes patients, potentially reducing injection frequency from daily to weekly.

Eli Lilly announced positive results from phase 3 trials of once-weekly insulin efsitora alfa, showing non-inferior A1C reduction compared to daily basal insulins in type 2 diabetes patients. Efsitora demonstrated similar safety and tolerability profiles, with potential to simplify insulin therapy and reduce patient burden.

Innovent Biologics announces multiple mazdutide clinical study results to be presented at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent, founded in 2011, develops high-quality medicines for various diseases.

Innovent Biologics to present multiple mazdutide clinical study results at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.

Tirzepatide, in Zepbound, reduced type 2 diabetes risk by 94% in obese or overweight adults with pre-diabetes, with sustained weight loss. Potential side effects include stomach and kidney issues, low blood sugar, and allergic reactions. Long-term effectiveness remains uncertain.

Deepak Bhatt, a prominent cardiologist, discussed common pitfalls in interpreting clinical trial data at the ESC Congress 2024. His work, cited over 275,000 times, focuses on pivotal trials like REDUCE-IT and SCORED. Bhatt highlighted the 17-year lag between scientific discovery and its adoption into clinical practice.